Julio Garcia-Aguilar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8354555/publications.pdf

Version: 2024-02-01

242 papers

17,485 citations

18482 62 h-index 125 g-index

250 all docs

250 docs citations

250 times ranked

13069 citing authors

#	Article	IF	CITATIONS
1	Chemoradiation and Local Excision Versus Total Mesorectal Excision for T2NO Rectal Cancer. Annals of Surgery, 2023, 277, e96-e102.	4.2	11
2	Deep Learning-Based Model for Identifying Tumors in Endoscopic Images From Patients With Locally Advanced Rectal Cancer Treated With Total Neoadjuvant Therapy. Diseases of the Colon and Rectum, 2023, 66, 383-391.	1.3	6
3	A <scp>SMAD4</scp> â€modulated gene profile predicts diseaseâ€free survival in stage <scp>II</scp> and <scp>III</scp> colorectal cancer. Cancer Reports, 2022, 5, e1423.	1.4	10
4	Factors Associated With Premature Ovarian Insufficiency in Young Women With Locally Advanced Rectal Cancer Treated With Pelvic Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100801.	1.2	6
5	Rectal Cancer: Nonoperative Management. , 2022, , 491-508.		0
6	Timing of Primary Tumor Resection in Synchronous Metastatic Colon Cancer Patients Undergoing Hepatic Arterial Infusion Pump Placement. Annals of Surgical Oncology, 2022, 29, 2044-2051.	1.5	6
7	MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology. Diseases of the Colon and Rectum, 2022, 65, 489-496.	1.3	9
8	ASO Visual Abstract: Timing of Primary Tumor Resection in Synchronous Metastatic Colon Cancer Patients Undergoing Hepatic Arterial Infusion Pump Placement. Annals of Surgical Oncology, 2022, 29, 2054-2055.	1.5	0
9	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist, 2022, 27, 380-388.	3.7	12
10	Transcriptomic profiling to identify subsets of immune hot locally advanced rectal adenocarcinomas with favorable outcomes after neoadjuvant treatment Journal of Clinical Oncology, 2022, 40, 155-155.	1.6	0
11	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
12	Unresected Left-sided Colon Tumors in Asymptomatic Metastatic Patients are Associated with Higher Rates of Complications than Unresected Right-sided Tumors. European Journal of Surgical Oncology, 2022, 48, e48.	1.0	0
13	Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. European Radiology, 2022, 32, 4991-5003.	4.5	32
14	KRAS Mutants Upregulate Integrin \hat{l}^24 to Promote Invasion and Metastasis in Colorectal Cancer. Molecular Cancer Research, 2022, 20, 1305-1319.	3.4	3
15	Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography. Diagnostics, 2022, 12, 984.	2.6	2
16	Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature, 2022, 605, 139-145.	27.8	38
17	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. Journal of Clinical Oncology, 2022, 40, 2546-2556.	1.6	292
18	The Multimodal Management of Locally Advanced Rectal Cancer: Making Sense of the New Data. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 264-277.	3.8	7

#	Article	IF	CITATIONS
19	PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 2022, 386, 2363-2376.	27.0	588
20	Predictors of operative difficulty in robotic low anterior resection for rectal cancer. Colorectal Disease, 2022, 24, 1318-1324.	1.4	2
21	Neoadjuvant and adjuvant therapy for local excision of rectal cancer. Seminars in Colon and Rectal Surgery, 2022, , 100900.	0.3	0
22	Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. British Journal of Anaesthesia, 2022, 129, 172-181.	3.4	9
23	Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial. Cancers, 2022, 14, 3204.	3.7	11
24	Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2021, 11, 13-25.	2.1	67
25	Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
26	Primary Tumor-Related Complications and Salvage Outcomes in Patients with Metastatic Rectal Cancer and an Untreated Primary Tumor. Diseases of the Colon and Rectum, 2021, 64, 45-52.	1.3	7
27	Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin. Annals of Surgical Oncology, 2021, 28, 1109-1117.	1.5	5
28	Rectal cancer with complete endoscopic response after neoadjuvant therapy: what is the meaning of a positive MRI?. European Radiology, 2021, 31, 4731-4738.	4.5	16
29	Comparative analysis of the Memorial Sloan Kettering Bowel Function Instrument and the Low Anterior Resection Syndrome Questionnaire for assessment of bowel dysfunction in rectal cancer patients after low anterior resection. Colorectal Disease, 2021, 23, 451-460.	1.4	16
30	Interpreting the RAPIDO trial: factors to consider. Lancet Oncology, The, 2021, 22, e87-e88.	10.7	1
31	Evaluating the Validity of the Clavien–Dindo Classification in Colectomy Studies: A 90-Day Cost of Care Analysis. Diseases of the Colon and Rectum, 2021, 64, 1426-1434.	1.3	8
32	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	1.6	34
33	Endoscopic Feature and Response Reproducibility in Tumor Assessment after Neoadjuvant Therapy for Rectal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 5205-5223.	1.5	11
34	Effect of a Predictive Model on Planned Surgical Duration Accuracy, Patient Wait Time, and Use of Presurgical Resources. JAMA Surgery, 2021, 156, 315.	4.3	37
35	ASO Author Reflections: Endoscopic Rectal Cancer Response to Neoadjuvant Therapy: Qualitative or Quantitative Interpretation?. Annals of Surgical Oncology, 2021, 28, 5224-5225.	1.5	1
36	The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer Journal of Clinical Oncology, 2021, 39, 12065-12065.	1.6	1

#	Article	IF	Citations
37	Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial Journal of Clinical Oncology, 2021, 39, 3509-3509.	1.6	25
38	Non Surgical Treatment in Patients With Advanced Rectal Cancer. CirugÃa Española (English Edition), 2021, 99, 401-403.	0.1	1
39	A Coordinated Clinical Center for Young Onset Colorectal Cancer. Oncologist, 2021, 26, 625-629.	3.7	8
40	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. Molecular Oncology, 2021, 15, 2766-2781.	4.6	7
41	Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Acta Oncol \tilde{A}^3 gica, 2021, 60, 1308-1316.	1.8	6
42	Prevalence of nodal involvement in rectal cancer after chemoradiotherapy. British Journal of Surgery, 2021, 108, 1251-1258.	0.3	11
43	Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer. International Journal of Colorectal Disease, 2021, 36, 2603-2611.	2.2	7
44	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nature Reviews Clinical Oncology, 2021, 18, 805-816.	27.6	93
45	Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy. Diseases of the Colon and Rectum, 2021, 64, 1463-1470.	1.3	22
46	Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy. Advances in Surgery, 2021, 55, 89-107.	1.3	8
47	Rectal cancer lateral lymph nodes: multicentre study of the impact of obturator and internal iliac nodes on oncological outcomes. British Journal of Surgery, 2021, 108, 205-213.	0.3	42
48	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. Diseases of the Colon and Rectum, 2021, 64, 555-562.	1.3	8
49	Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. Annals of Surgical Oncology, 2021, , 1.	1.5	4
50	ASO Author Reflections: Identifying Rectal Cancer Patients Suitable for Watch-and-Wait. Annals of Surgical Oncology, 2021, , 1.	1.5	0
51	ASO Visual Abstract: Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. Annals of Surgical Oncology, 2021, , 1.	1.5	0
52	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	5.9	16
53	ASO Author Reflections: Hepatic Arterial Infusion Pump Can Be Placed Simultaneously with Primary Tumor Resection in Colon Cancer Patients with Synchronous Metastases. Annals of Surgical Oncology, 2021, , 1.	1.5	0
54	Identifying Diagnostic MicroRNAs and Investigating Their Biological Implications in Rectal Cancer. JAMA Network Open, 2021, 4, e2136913.	5.9	3

#	Article	IF	CITATIONS
55	Comparing outcomes of robotic <i>versus</i> open mesorectal excision for rectal cancer. BJS Open, 2021, 5, .	1.7	6
56	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer, 2020, 20, 201-213.	1.9	8
57	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. Oncolmmunology, 2020, 9, 1841948.	4.6	3
58	Definitive Intensity-Modulated Radiation Therapy For Anal Squamous Cell Carcinoma: Outcomes And Toxicities From A Large Single Institution Experience. International Journal of Radiation Oncology Biology Physics, 2020, 108, e633-e634.	0.8	0
59	Confirmation of complete mesocolic excision with central vascular ligation. European Journal of Surgical Oncology, 2020, 46, 1386-1387.	1.0	1
60	Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
61	Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case–Control Study. Diseases of the Colon and Rectum, 2020, 63, 897-902.	1.3	41
62	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nature Cancer, 2020, 1, 28-45.	13.2	137
63	Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. Journal of the American College of Surgeons, 2020, 230, 669-675.	0.5	16
64	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	7.0	62
65	Watch and Wait in Rectal Cancer or More Wait and See?. JAMA Surgery, 2020, 155, 657.	4.3	18
66	Outcome measures in multimodal rectal cancer trials. Lancet Oncology, The, 2020, 21, e252-e264.	10.7	56
67	Intracorporeal Anastomoses in Minimally Invasive Right Colectomies Are Associated With Fewer Incisional Hernias and Shorter Length of Stay. Diseases of the Colon and Rectum, 2020, 63, 685-692.	1.3	40
68	Clinical utility of radiomics at baseline rectal MRI to predict complete response of rectal cancer after chemoradiation therapy. Abdominal Radiology, 2020, 45, 3608-3617.	2.1	45
69	Organ Preservation in Rectal Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1880-1888.	1.7	17
70	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. Advances in Radiation Oncology, 2020, 5, 687-689.	1,2	33
71	Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial Journal of Clinical Oncology, 2020, 38, 4008-4008.	1.6	168
72	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma Journal of Clinical Oncology, 2020, 38, TPS4123-TPS4123.	1.6	3

#	Article	lF	CITATIONS
73	Genomic characterization of rectal cancer and molecular determinants of response to neoadjuvant chemoradiotherapy Journal of Clinical Oncology, 2020, 38, 192-192.	1.6	0
74	Monitoring an Ongoing Enhanced Recovery After Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases. Clinics in Surgery, 2020, 5, .	0.8	3
75	A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resection. Hpb, 2019, 21, 181-186.	0.3	8
76	Looking Forward, Not Backward, on Watch and Wait for Rectal Cancerâ€"In Reply. JAMA Oncology, 2019, 5, 1231.	7.1	2
77	Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy. JAMA Surgery, 2019, 154, e192172.	4.3	141
78	Adipose tissue grafting for management of persistentÂanastomotic leak after low anterior resection. Techniques in Coloproctology, 2019, 23, 981-985.	1.8	0
79	Genomic stratification beyond Ras/Bâ€Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Medicine, 2019, 8, 6538-6548.	2.8	8
80	Initial Results of the First Clinical Trial of a Novel Unidirectional Permanent Device for Intraoperative Brachytherapy. Brachytherapy, 2019, 18, S30.	0.5	0
81	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	30.7	320
82	Fully Robotic Resection of a Splenic Flexure Tumor with Intracorporeal Anastomosis. Diseases of the Colon and Rectum, 2019, 62, 257-257.	1.3	2
83	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. JNCI Cancer Spectrum, 2019, 3, pkz015.	2.9	16
84	Assessment of the Value of Comorbidity Indices for Risk Adjustment in Colorectal Surgery Patients. Annals of Surgical Oncology, 2019, 26, 2797-2804.	1.5	13
85	Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in shortâ€term outcomes. Colorectal Disease, 2019, 21, 1140-1150.	1.4	16
86	Complete mesocolic excision and central vascular ligation for right colon cancer: an introduction for abdominal radiologists. Abdominal Radiology, 2019, 44, 3518-3526.	2.1	12
87	Role of the Interval from Completion of Neoadjuvant Therapy to Surgery in Postoperative Morbidity in Patients with Locally Advanced Rectal Cancer. Annals of Surgical Oncology, 2019, 26, 2019-2027.	1.5	15
88	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. Clinical Colorectal Cancer, 2019, 18, 167-174.	2.3	3
89	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. Journal of Gastrointestinal Surgery, 2019, 23, 794-799.	1.7	2
90	Definition of the Rectum. Annals of Surgery, 2019, 270, 955-959.	4.2	96

#	Article	IF	CITATIONS
91	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology, 2019, 32, 110-121.	5.5	28
92	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clinical Cancer Research, 2019, 25, 1948-1956.	7.0	71
93	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncology, 2019, 5, e185896.	7.1	347
94	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. Journal of Gastrointestinal Surgery, 2019, 23, 800-807.	1.7	21
95	Use of the Xi robotic platform for total abdominal colectomy: a step forward in minimally invasive colorectal surgery. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 966-971.	2.4	15
96	Chemoradiotherapy and Local Excision for Organ Preservation in Early Rectal Cancer—The End of the Beginning?. JAMA Surgery, 2019, 154, 54.	4.3	4
97	Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer. European Radiology, 2019, 29, 1104-1113.	4.5	23
98	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. European Radiology, 2019, 29, 1733-1742.	4.5	9
99	A KRAS mutation is associated with an immunosuppressive tumor microenvironment in mismatch-repair proficient colorectal cancer Journal of Clinical Oncology, 2019, 37, 609-609.	1.6	4
100	Rectal Cancer: Operative Treatment Transabdominal. , 2019, , 419-444.		0
101	Organ preservation in rectal cancer patients treated with total neoadjuvant therapy Journal of Clinical Oncology, 2019, 37, 692-692.	1.6	0
102	KRAS mutation is associated with upregulation of integrin beta-4 expression leading to tumor invasion in colorectal cancer Journal of Clinical Oncology, 2019, 37, 576-576.	1.6	1
103	MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. Radiology, 2018, 287, 833-843.	7.3	257
104	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. American Journal of Surgical Pathology, 2018, 42, 705-714.	3.7	61
105	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncology, 2018, 4, 309.	7.1	146
106	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, e180071.	7.1	404
107	Reprint to: Fistulotomy. Seminars in Colon and Rectal Surgery, 2018, 29, 183-187.	0.3	0
108	Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Diseases of the Colon and Rectum, 2018, 61, 1146-1155.	1.3	115

#	Article	IF	CITATIONS
109	Multidisciplinary, perioperative care bundle decreases surgical site infection in patients undergoing synchronous colorectal/liver resection. Hpb, 2018, 20, S19.	0.3	O
110	Effectiveness of a multidisciplinary patient care bundle for reducing surgical-site infections. British Journal of Surgery, 2018, 105, 1680-1687.	0.3	57
111	Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC) Journal of Clinical Oncology, 2018, 36, 3520-3520.	1.6	3
112	Non-operative management of rectal cancer: understanding tumor biology. Minerva Chirurgica, 2018, 73, 601-618.	0.8	3
113	Anorectal Function and Quality of Life in Patients With Early Stage Rectal Cancer Treated With Chemoradiation and Local Excision. Diseases of the Colon and Rectum, 2017, 60, 459-468.	1.3	19
114	Evolving application of minimally invasive cancer operations at a tertiary cancer center. Journal of Surgical Oncology, 2017, 115, 365-370.	1.7	7
115	Single Nucleotide Polymorphism TGF \hat{l}^21 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 97, 924-930.	0.8	10
116	Induction Chemotherapy Reduces Patient-Reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiation Therapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E174-E175.	0.8	0
117	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
118	Lymph node yield in right colectomy for cancer: a comparison of open, laparoscopic and robotic approaches. Colorectal Disease, 2017, 19, 888-894.	1.4	46
119	Organ-Preserving Strategies for the Management of Near-Complete Responses in Rectal Cancer after Neoadjuvant Chemoradiation. Clinics in Colon and Rectal Surgery, 2017, 30, 395-403.	1.1	14
120	Developing a robotic colorectal cancer surgery program: understanding institutional and individual learning curves. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 2820-2828.	2.4	61
121	Clinicopathologic Features of Young Onset Colorectal Cancer Patients: Results From a Large Cohort at a Single Cancer Center. American Journal of Gastroenterology, 2017, 112, S108.	0.4	1
122	Total neoadjuvant therapy for locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 662-662.	1.6	3
123	Clinical Complete Response after Neoadjuvant Chemoradiotherapy in Rectal Cancer: Operative or Non-Operative Management?. Difficult Decisions in Surgery: an Evidence-based Approach, 2017, , 191-203.	0.0	0
124	Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 92-102.	3.8	9
125	Reply to Crist \tilde{A}^3 bal and Co-authors' comment, deregulation of miR-92a in locally advanced rectal cancer. Genes Chromosomes and Cancer, 2016, 55, 613-613.	2.8	0
126	Integrated genomic profiling identifies micro <scp>RNA</scp> â€92a regulation of <scp>IQGAP</scp> 2 in locally advanced rectal cancer. Genes Chromosomes and Cancer, 2016, 55, 311-321.	2.8	9

#	Article	IF	Citations
127	Rectal Cancer: Neoadjuvant Therapy. , 2016, , 481-494.		1
128	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Annals of Surgical Oncology, 2016, 23, 2548-2555.	1.5	70
129	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
130	Incisional hernias after laparoscopic and robotic right colectomy. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2016, 20, 723-728.	2.0	37
131	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. Journal of Surgical Oncology, 2016, 114, 637-641.	1.7	35
132	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	5.5	144
133	Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nature Communications, 2016, 7, 12326.	12.8	78
134	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. European Radiology, 2016, 26, 4303-4312.	4.5	63
135	Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 92-102.	3.8	7
136	Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer, 2015, 15, 767.	2.6	276
137	Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation. Journal of the American College of Surgeons, 2015, 221, 430-440.	0.5	147
138	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 957-966.	10.7	524
139	Advances and Challenges in Treatment of Locally Advanced Rectal Cancer. Journal of Clinical Oncology, 2015, 33, 1797-1808.	1.6	150
140	Does Endoscopic Ultrasound Improve Detection of Locally Recurrent Anal Squamous-Cell Cancer?. Diseases of the Colon and Rectum, 2015, 58, 193-198.	1.3	7
141	Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncology, The, 2015, 16, 1537-1546.	10.7	326
142	Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. International Journal of Cancer, 2015, 137, 212-220.	5.1	94
143	Transanal surgery for cT1 rectal cancer: Patient selection, technique, and outcomes. Seminars in Colon and Rectal Surgery, 2015, 26, 20-25.	0.3	1
144	Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy Journal of Clinical Oncology, 2015, 33, 509-509.	1.6	22

#	Article	IF	CITATIONS
145	Accuracy of computed tomography in nodal staging of colon cancer patients. World Journal of Gastrointestinal Surgery, 2015, 7, 116.	1.5	18
146	Multiparametric MRI of Rectal Cancer in the Assessment of Response to Therapy. Diseases of the Colon and Rectum, 2014, 57, 790-799.	1.3	77
147	Optimizing Rectal Cancer Management. Diseases of the Colon and Rectum, 2014, 57, 252-259.	1.3	32
148	Failure of Evidence-Based Cancer Care in the United States. Annals of Surgery, 2014, 260, 625-632.	4.2	140
149	Management and Outcome of Perianal Paget's Disease. Diseases of the Colon and Rectum, 2014, 57, 747-751.	1.3	52
150	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. Journal of the National Cancer Institute, 2014, 106, .	6.3	179
151	Neoadjuvant Radiation Therapy Prior to Total Mesorectal Excision for Rectal Cancer is Not Associated with Postoperative Complications Using Current Techniques. Annals of Surgical Oncology, 2014, 21, 2295-2302.	1.5	14
152	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. Current Colorectal Cancer Reports, 2014, 10, 164-172.	0.5	4
153	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 513-519.	4.9	186
154	Race and Correlations Between Lymph Node Number and Survival for Patients with Gastric Cancer. Journal of Gastrointestinal Surgery, 2013, 17, 471-481.	1.7	14
155	The association of hospital volume with rectal cancer surgery outcomes. International Journal of Colorectal Disease, 2013, 28, 191-196.	2.2	51
156	Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer. European Radiology, 2013, 23, 3336-3344.	4.5	17
157	Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 2166-2171.	1.5	91
158	Locoregional Lymphadenectomy in the Surgical Management of Anorectal Melanoma. Annals of Surgical Oncology, 2013, 20, 2339-2344.	1.5	45
159	Phase 2 Timing of Rectal Cancer Response to Chemoradiation: Analysis of Radiation Therapy (RT). International Journal of Radiation Oncology Biology Physics, 2013, 87, S88.	0.8	1
160	Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer. Seminars in Colon and Rectal Surgery, 2013, 24, 119-124.	0.3	5
161	Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer, 2013, 119, 1106-1112.	4.1	16
162	What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy?. Annals of Surgical Oncology, 2013, 20, 1179-1184.	1.5	66

#	Article	IF	Citations
163	Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer, 2013, 119, 739-747.	4.1	45
164	Ask the Experts: Chemoradiotherapy and colorectal cancer. Colorectal Cancer, 2013, 2, 497-500.	0.8	0
165	Distribution of Residual Cancer Cells in the Bowel Wall After Neoadjuvant Chemoradiation in Patients With Rectal Cancer. Diseases of the Colon and Rectum, 2013, 56, 142-149.	1.3	90
166	Transanal Endoscopic Microsurgery Following Neoadjuvant Chemoradiation Therapy in Rectal Cancer. Diseases of the Colon and Rectum, 2013, 56, 1-3.	1.3	18
167	TP53 and Let-7a micro-RNA Regulate K-Ras Activity in HCT116 Colorectal Cancer Cells. PLoS ONE, 2013, 8, e70604.	2.5	22
168	Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World Journal of Gastrointestinal Surgery, 2013, 5, 321.	1.5	15
169	A giant rectal villous adenoma with a malicious intent. Gastrointestinal Cancer Research: GCR, 2013, 6, 144-9.	0.7	1
170	Chromosomal Copy Number Alterations Are Associated with Persistent Lymph Node Metastasis After Chemoradiation in Locally Advanced Rectal Cancer. Diseases of the Colon and Rectum, 2012, 55, 677-685.	1.3	16
171	Organ-preserving therapy for rectal cancer. Colorectal Cancer, 2012, 1, 537-547.	0.8	0
172	Gene Expression Variations in Microsatellite Stable and Unstable Colon Cancer Cells. Journal of Surgical Research, 2012, 174, 1-6.	1.6	22
173	Evaluation of Lymphadenectomy in Patients Receiving Neoadjuvant Radiotherapy for Rectal Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 3713-3718.	1.5	15
174	Robot-assisted total mesorectal excision: is there a learning curve?. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 2471-2476.	2.4	82
175	Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. International Journal of Molecular Sciences, 2012, 13, 12153-12168.	4.1	171
176	A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2NO Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial. Annals of Surgical Oncology, 2012, 19, 384-391.	1.5	291
177	Socioeconomic Factors Impact Colon Cancer Outcomes in Diverse Patient Populations. Journal of Gastrointestinal Surgery, 2012, 16, 692-704.	1.7	43
178	Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma. International Journal of Colorectal Disease, 2012, 27, 737-749.	2,2	10
179	The evolution of surgical technique for total gastrectomy over a 12-year period: a single institution's experience. American Surgeon, 2012, 78, 1054-8.	0.8	4
180	An appraisal of radiofrequency ablation and surgical resection for hepatocellular carcinoma: results from the surveillance, epidemiology, and end results registry. American Surgeon, 2012, 78, 1091-5.	0.8	4

#	Article	IF	CITATIONS
181	<i>Selection Criteria for Complete Cytoreduction after Cytoreductive Surgery for Peritoneal Surface Malignancy: Lessons Learned from Our First Series of Patients</i> i>American Surgeon, 2011, 77, 430-437.	0.8	2
182	<i>Surgical Complications and Pathologic Complete Response after Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer i> American Surgeon, 2011, 77, 1281-1285.</i>	0.8	18
183	An Interaction of Race and Ethnicity With Socioeconomic Status in Rectal Cancer Outcomes. Annals of Surgery, 2011, 253, 647-654.	4.2	57
184	Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer. Annals of Surgery, 2011, 254, 486-493.	4.2	147
185	Optimal Timing of Surgery After Chemoradiation for Advanced Rectal Cancer. Annals of Surgery, 2011, 254, 97-102.	4.2	272
186	Venous Thromboembolic Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 714-777.	4.9	108
187	Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes Chromosomes and Cancer, 2011, 50, 689-699.	2.8	33
188	Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer, 2011, 117, 5493-5499.	4.1	24
189	Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME Journal of Clinical Oncology, 2011, 29, 3514-3514.	1.6	19
190	Selection criteria for complete cytoreduction after cytoreductive surgery for peritoneal surface malignancy: lessons learned from our first series of patients. American Surgeon, 2011, 77, 430-7.	0.8	1
191	Surgical complications and pathologic complete response after neoadjuvant chemoradiation in locally advanced rectal cancer. American Surgeon, 2011, 77, 1281-5.	0.8	12
192	Robotic Colorectal Surgery: For Whom and for What?. Diseases of the Colon and Rectum, 2010, 53, 969-970.	1.3	46
193	Oncologic Outcomes of Robotic-Assisted Total Mesorectal Excision for the Treatment of Rectal Cancer. Annals of Surgery, 2010, 251, 882-886.	4.2	150
194	An Increase in Compliance With the Surgical Care Improvement Project Measures Does Not Prevent Surgical Site Infection in Colorectal Surgery. Diseases of the Colon and Rectum, 2010, 53, 24-30.	1.3	82
195	Validation of the Risk Index Category as a Predictor of Surgical Site Infection in Elective Colorectal Surgery. Diseases of the Colon and Rectum, 2010, 53, 721-727.	1.3	41
196	Multicentric Study on Robotic Tumor-Specific Mesorectal Excision for the Treatment of Rectal Cancer. Annals of Surgical Oncology, 2010, 17, 1614-1620.	1.5	238
197	Totally laparoscopic right colectomy with transvaginal specimen extraction: the authors' initial institutional experience. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2048-2052.	2.4	67
198	Molecular diagnosis of pathologic complete response (pCR) to neoadjuvant chemoradiation therapy (CRT) in patients with locally advanced rectal cancer (LARC). Journal of the American College of Surgeons, 2010, 211, S13-S14.	0.5	0

#	Article	IF	Citations
199	Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC). International Journal of Radiation Oncology Biology Physics, 2010, 78, S53-S54.	0.8	0
200	Optimal Management of Small Rectal Cancers: TAE, TEM, or TME?. Surgical Oncology Clinics of North America, 2010, 19, 743-760.	1.5	9
201	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2010, 11, 835-844.	10.7	1,532
202	Fistulotomy. Seminars in Colon and Rectal Surgery, 2009, 20, 18-23.	0.3	1
203	Treatment of Transsphincteric Anal Fistulas. Diseases of the Colon and Rectum, 2009, 52, 692-697.	1.3	60
204	Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons, and The American Society of Colon and Rectal Surgeons. Diseases of the Colon and Rectum, 2009, 52, 1-3.	1.3	6
205	Implementation of Quality Measures to Reduce Surgical Site Infection in Colorectal Patients. Diseases of the Colon and Rectum, 2008, 51, 1004-1009.	1.3	51
206	The Future of Surgical Management of Colorectal Cancer. Diseases of the Colon and Rectum, 2008, 51, 1455-1458.	1.3	1
207	Refractory Lower Gastrointestinal Bleeding from Portal Hypertensive Colopathy. Journal of the American College of Surgeons, 2008, 207, 613.	0.5	6
208	Local Excision for Rectal Carcinoma. Clinical Colorectal Cancer, 2008, 7, 376-385.	2.3	27
209	Dartos Muscle Interposition Flap for the Treatment of Rectourethral Fistulas. Diseases of the Colon and Rectum, 2007, 50, 1849-1855.	1.3	32
210	Aetiology and surgical management of toxic megacolon. Colorectal Disease, 2006, 8, 195-201.	1.4	54
211	Clinical patterns of metastasis. Cancer and Metastasis Reviews, 2006, 25, 221-232.	5.9	123
212	The Mechanism of Microsatellite Instability Is Different in Synchronous and Metachronous Colorectal Cancer. Journal of Gastrointestinal Surgery, 2005, 9, 329-335.	1.7	22
213	Mechanisms of Microsatellite Instability in Colorectal Cancer Patients in Different Age Groups. Diseases of the Colon and Rectum, 2005, 48, 2061-2069.	1.3	29
214	The Effect of Circumferential Tumor Location in Clinical Outcomes of Rectal Cancer Patients Treated With Total Mesorectal Excision. Diseases of the Colon and Rectum, 2005, 48, 2249-2257.	1.3	55
215	Endorectal Ultrasound in the Management of Patients With Malignant Rectal Polyps. Diseases of the Colon and Rectum, 2005, 48, 910-917.	1.3	12
216	Extended Abdominoperineal Resection. Seminars in Colon and Rectal Surgery, 2005, 16, 136-146.	0.3	0

#	Article	IF	CITATIONS
217	Endorectal Ultrasound in the Follow-Up of Rectal Cancer Patients Treated by Local Excision or Radical Surgery. Diseases of the Colon and Rectum, 2004, 47, 818-824.	1.3	50
218	Total mesorectal excision for rectal cancer: The truth lies underneath. World Journal of Surgery, 2004, 28, 113-116.	1.6	18
219	A Pathologic Complete Response to Preoperative Chemoradiation Is Associated With Lower Local Recurrence and Improved Survival in Rectal Cancer Patients Treated by Mesorectal Excision. Diseases of the Colon and Rectum, 2003, 46, 298-304.	1.3	334
220	Quality of Life After Subtotal Colectomy for Slow-Transit Constipation. Diseases of the Colon and Rectum, 2003, 46, 433-440.	1.3	109
221	Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer, 2003, 98, 48-54.	4.1	31
222	Cutting seton <i>versus</i> two-stage seton fistulotomy in the surgical management of high anal fistula. British Journal of Surgery, 2003, 85, 243-245.	0.3	184
223	Accuracy of Endorectal Ultrasonography in Preoperative Staging of Rectal Tumors. Diseases of the Colon and Rectum, 2002, 45, 10-15.	1.3	325
224	Salvage Radical Surgery After Failed Local Excision for Early Rectal Cancer. Diseases of the Colon and Rectum, 2002, 45, 875-879.	1.3	139
225	Pelvic wall involvement denotes a poor prognosis in T4 rectal cancer. Diseases of the Colon and Rectum, 2001, 44, 1676-1681.	1.3	25
226	Treatment of locally recurrent rectal cancer. Diseases of the Colon and Rectum, 2001, 44, 1743-1748.	1.3	112
227	INCIDENCE, DISTRIBUTION AND MECHANISMS OF MICROSATELLITE INSTABILITY IN DIFFERENT COLORECTAL CANCER AGE GROUPS. Annals of the College of Surgeons of Hong Kong, 2001, 5, A23-A23.	0.0	0
228	Local Excision of Rectal Cancer Without Adjuvant Therapy. Annals of Surgery, 2000, 231, 345-351.	4.2	315
229	Role of local excision in the treatment of rectal cancer. Journal of Surgical Oncology, 2000, 19, 367-375.	1.4	63
230	Is local excision adequate therapy for early rectal cancer?. Diseases of the Colon and Rectum, 2000, 43, 1064-1071.	1.3	401
231	Molecular prognostic factors in rectal cancer treated by radiation and surgery. Diseases of the Colon and Rectum, 2000, 43, 451-459.	1.3	65
232	Modification of the gluteal perforator-based flap for reconstruction of the posterior vagina. Diseases of the Colon and Rectum, 2000, 43, 1020-1022.	1.3	19
233	Patient satisfaction after surgical treatment for fistula-in-ano. Diseases of the Colon and Rectum, 2000, 43, 1206-1212.	1.3	121
234	Incontinence after lateral internal sphincterotomy. Diseases of the Colon and Rectum, 1998, 41, 423-427.	1.3	94

#	Article	IF	CITATIONS
235	Risks of the Minimal Access Approach for Laparoscopic Surgery: Multivariate Analysis of Morbidity Related to Umbilical Trocar Insertion. World Journal of Surgery, 1997, 21, 529-533.	1.6	203
236	Open vs. closed sphincterotomy for chronic anal fissure. Diseases of the Colon and Rectum, 1996, 39, 440-443.	1.3	214
237	Anal fistula surgery. Diseases of the Colon and Rectum, 1996, 39, 723-729.	1.3	463
238	Isoperistaltic jejunal interposition for intractable postgastrectomy alkaline reflux gastritis. Journal of the American College of Surgeons, 1995, 180, 648-53.	0.5	14
239	The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands Journal of Cell Biology, 1993, 120, 1031-1043.	5.2	518
240	Characterization of the p150,95 leukocyte integrin alpha subunit (CD11c) gene promoter. Identification of cis-acting elements. Journal of Biological Chemistry, 1993, 268, 1187-93.	3.4	50
241	ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18) Journal of Cell Biology, 1990, 111, 3129-3139.	5.2	877
242	Genomic structure of an integrin alpha subunit, the leukocyte p150,95 molecule. Journal of Biological Chemistry, 1990, 265, 2782-8.	3 . 4	56